A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese kailuan female cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 2, 2015, Pages 459-465

  Wang, Gang ^a   Li, Ni ^b   Chang, Sheng ^b   Bassig, Bryan A ^c   Guo, Lanwei ^b   Ren, Jiansong ^b   Su, Kai ^b   Li, Fang ^b   Chen, Shuohua ^d   Wu, Shouling ^d   Zou, Yuhuan ^a   Dai, Min ^b   Zheng, Tongzhang ^c   He, Jie ^b  

^a Kailuan (Group) Limited Liability Corporation   (China)

^b CANCER HOSPITAL   (China)

^c YALE UNIVERSITY   (United States)

^d Kailuan Group   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CHINESE; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; METABOLISM; NEOPLASMS;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; CHINA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84922739877     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1112     Document Type: Article

References (33)

1. Rakoff-Nahoum S. Why Cancer and Inflammation? Yale J Biol Med 2006;79:123-30.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
3. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, et al. Association between prediagnostic biomarkersof inflammation and endo-thelial function and cancer risk: a nested case-control study. Am J Epidemiol 2013;177:3-13.
4. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250-5.
5. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107: 499-511.
6. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.
7. Yigit E, Gonullu G, Yucel I, Turgut M, Erdem D, Cakar B. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur J Intern Med 2008;19:602-7.
8. Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev 2013;14:243-8.
9. Xue H, Wang J, Hou J, Zhu H, Gao J, Chen S, et al. Association of ideal cardiovascular metrics and serum high-sensitivity c-reactive protein in hypertensive population. PLoS ONE 2013;8:e81597.
10. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
11. International Agency for Researchon Cancer. GLOBOCAN 2012 Database. [Accessed October 26, 2014]. http://globocan.iarc.fr/Default.aspx.
12. Pasceri V, Cammarota G. C-reactive protein and risk of colon cancer. JAMA 2004;291:2818-9.
13. Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007;121:2373-80.
14. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-21.
15. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated Biomarkers ofinflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009;27: 3437-44.
16. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the women's health initiative. Cancer Res 2003; 63:6096-101.
17. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006;24:5216-22.
18. Prizment AE, Folsom AR, Dreyfus J, Anderson KE, Visvanathan K, Joshu CE, et al. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. Cancer Causes Control 2013;24:2077-87.
19. Ollberding NJ, Kim Y, Shvetsov YB, Wilkens LR, Franke AA, Cooney RV, et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res 2013;6:188-95.
20. Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2007;99:890-4.
21. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413-8.
22. Gaudet MM, Patel AV, Teras LR, Sun J, Campbell PT, Stevens VL, et al. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet 2013;4:156-66.
23. Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
24. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005;142:425-32.
25. Prizment AE, Anderson KE, Visvanathan K, Folsom AR. Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 2011;20:297-307.
26. Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, et al. Circulating inflammation markers and prospective risk of lung cancer. J Natl Cancer Inst 2013;105:1871-80.
27. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101-14.
28. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-33.
29. Mousavi-Jarrrahi SH, Kasaeian A, Mansori K, Ranjbaran M, Khodadost M, Mosavi-Jarrahi A. Addressing the younger age at onset in breast cancer patients in Asia: an age-period-cohort analysis of fifty years of quality data from the International Agency for Research on Cancer. ISRN Oncol 2013; http://dx.doi.org/10.1155/2013/429862.
30. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47:444-50.
31. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001;47:426-30.
32. Wu S, Li Y, Jin C, Yang P, Li D, Li H, et al. Intra-individual variability of high-sensitivity C-reactive protein in Chinese general population. Int J Cardiol 2012;157:75-9.
33. Tsai AC, Tsai HJ. The association of age, gender, body fatness and lifestyle factors with plasma C-reactive protein concentrations in older Taiwanese. J Nutr Health Aging 2010;14:412-6.